Objective response rate (ORR)

Up to 40 clinical study sites globally

Zsiros E, Tsuji T, and Odunsi, K. 2015. Adoptive T

For more information, please contact

Hillman Cancer Center, Pittsburgh, PA;


Monk BJ, Sill MW, Burger RA, Gray HJ, Buekers TE, and


C

329a

89x821

Overall survival (OS)

Recurrent, metastatic, or persistent cervical carcinoma presents a high unmet medical need with low survival rates and with limited effective treatment options.

Presence of TIL have been correlated with improved outcomes in cervical carcinoma.

TIL have demonstrated efficacy in other solid tumors including responses in heavily pretreated patients irrespective of prior therapy, including checkpoint inhibitors.

Pilot data using TIL therapy for the treatment of cervical carcinoma has demonstrated the potential for long-term durable complete responses.

This study aims to assess the potential of TIL therapy for the treatment of cervical cancer patients with recurrent, metastatic, or persistent disease.

References


© 2018, Iovance Biotherapeutics